ALBUPAD, a Pharma enabler :
merging biological safety with engineered structural control
Built on a protein with an established regulatory profile, ALBUPAD offers Pharma partners a safe, scalable, and differentiating platform for next-generation therapeutics.
Albumin is inherently biocompatible, non-immunogenic, and widely used in approved formulations. Yet its potential as a structured solid matrix has remained inaccessible due to the lack of a controllable shaping technology. ALBUPAD fills this innovation gap by engineering albumin into stable solid forms – microdiscs, films, and 3D matrices – with tunable mechanical properties, porosity, and degradation kinetics.
ALBUPAD provides key strategic advantages to Pharma companies:
- a clean regulatory path thanks to a human-origin excipient already familiar to health authorities;
- a scalable process to manufacture a biomaterial that withstands standard sterilization process, without loss of integrity or functionality, and that is inherently visible by ultrasound or MRI
- a proprietary programmable material capable of supporting sustained release, targeted delivery – which may benefit from the spontaneous targeting of cancer tissues by Albumin – and combination-device formats;
- a versatile platform that can be rapidly adapted to multiple therapeutic areas, types of active principles – such as small molecules, peptides, proteins or nucleotides, and routes of administration.
Licensing & BD Models range from exclusive or semi-exclusive licensing, to co-development and joint IP, and technology transfer and manufacturing support.
Business Model
B2B
Pharmaceutical Industry
Out Licencing + R&D
Assets:
• Expandable IP portfolio + expertise
• Production capacity ( prototypes TRL 1-5, ≈ kg)
• CRO/CDMO & Academic partners
Feasibility Validation
TRL 1 – 4 (3 à 6 months)
Co-Development
TRL 5 GLP (12 à 24 months)
Out Licencing
TRL 6 – 8 GLP / GMP
CORE PATENT
APPLICATION SPECIFIC PATENTS